黄葵胶囊联合利拉鲁肽治疗早期糖尿病肾病患者的临床价值  

Clinical value of Huangkui capsule combined with liraglutide in the treatment of patients with early diabetic nephropathy

作　　者：朱倩雯 ZHU Qian-wen(Dalian Ganjingzi District People's Hospital,Dalian 116000,China)

机构地区：[1]大连市甘井子区人民医院,116000

出　　处：《中国现代药物应用》2023年第17期135-137,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析黄葵胶囊联合利拉鲁肽治疗早期糖尿病肾病患者的临床应用价值。方法68例早期糖尿病肾病患者,根据随机分配法分为观察组和对照组,每组34例。对照组患者实施黄葵胶囊联合胰岛素治疗,观察组实施黄葵胶囊联合利拉鲁肽治疗。比较两组患者治疗前后的血糖控制情况[空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)]及肾功能指标[尿白蛋白排泄率(UAER)以及尿微量白蛋白/肌酐比值(UACR)]。结果治疗后,两组FBG、HbA1c、2 h PG水平均低于本组治疗前,且观察组FBG、HbA1c、2 h PG水平分别为(6.31±1.13)mmol/L、(5.42±1.36)%、(8.93±2.18)mmol/L,低于对照组的(8.04±1.16)mmol/L、(7.52±0.89)%、(10.87±2.41)mmol/L,差异有统计学意义(P<0.05)。治疗后,观察组UAER、UACR水平分别为(57.26±15.33)μg/min、(64.52±13.16)mg/g,均低于对照组的(68.74±15.12)μg/min、(77.68±14.34)mg/g,差异有统计学意义(P<0.05)。结论临床上针对早期糖尿病肾病患者应用黄葵胶囊联合利拉鲁肽治疗效果显著,能够改善患者肾功能指标,有效控制患者血糖。Objective To analyze the clinical practical value of Huangkui capsule combined with liraglutide in the treatment of patients with early diabetic nephropathy.Methods A total of 68 patients with early diabetic nephropathy were randomly divided into observation group and control group,with 34 cases in each group.The control group was treated with Huangkui capsule and insulin,and the observation group was treated with Huangkui capsule and liraglutide.Both groups were compared in terms of blood glucose control[fasting blood glucose(FBG),glycated hemoglobin(HbA1c),2 h postprandial glucose(2 h PG)]and renal function indicators[urinary albumin excretion rate(UAER)and urinary microalbumin/creatinine ratio(UACR)]before and after treatment.Results After treatment,the levels of FBG,HbA1c and 2 h PG in both groups were lower than those before treatment in this group;the levels of FBG,HbA1c and 2 h PG in the observation group were(6.31±1.13)mmol/L,(5.42±1.36)%and(8.93±2.18)mmol/L,which were lower than those of(8.04±1.16)mmol/L,(7.52±0.89)%and(10.87±2.41)mmol/L in the control group;the differences were statistically significant(P<0.05).After treatment,UAER and UACR levels in the observation group were(57.26±15.33)μg/min and(64.52±13.16)mg/g,which were lower than those of(68.74±15.12)μg/min and(77.68±14.34)mg/g in the control group,and the differences were statistically significant.(P<0.05).Conclusion Huangkui capsule combined with liraglutide has significant effect in the treatment of early diabetic nephropathy patients,and can improve the renal function index and effectively control the blood glucose of patients.

关 键 词：黄葵胶囊 利拉鲁肽 早期糖尿病肾病 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]